Developer docs
API playgroundTry for free, no card

Search company profiles

Isala

Full company profile

uuid004o1fv

Namestring
Isala
Legal namestring
Isala
Websiteurl
isala.be
Company typeenum
Private
Founded yearint
2020
Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
11–50
akta.pro rankint
HeadquartersAntwerp, Belgium
HQ citystring
Antwerp
HQ countrystring
Belgium
HQ regionstring
Europe
Markets served

Serves global market

Offices1 record

Each record includes

City, Country, Type, Description, Source

Keyword5 values
vaginal microbiome research, citizen science platform, women's health research, DNA sequencing analysis, microbiome mapping
Industry5 codes
PRIMARYHLAAAFAH
Microbiome Diagnostics & Biomarker Platforms (gut/skin/oral/vaginal)
SECONDARYHLAAAFAI
Microbiome Analytics, Sequencing & Bioinformatics Platforms
SECONDARYHLAGANAH
Microbiome & Metagenomics Services
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Specialty Lab Services (Genomics/Proteomics/Cellomics)
SECONDARYHLAAAFAK
Microbiome Clinical Development & Translational Services (trial design, endpoints, sampling)
SECONDARYHLAGANAA
Genomics & Next-Generation Sequencing (NGS) Services
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Specialty Lab Services (Genomics/Proteomics/Cellomics)
NAICS code1 code
  • Medical Laboratories621511
SIC code1 code
  • In Vitro & In Vivo Diagnostic Substances2835
Product category
Microbiome Research
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model1 record
1Research Grants and Institutional Funding
TypeAffiliate Referral
Description

Isala is primarily funded through research grants from institutional sources. Primary funding comes from the European Research Council (ERC) under Horizon 2020 (Grant agreement 852600 Lacto-Be). Additional funding from the University of Antwerp, and project-specific grants such as the Biocodex Microbiota Foundation Belux Grant 2024. The project also receives support through donations and sponsorship packages (Gold €20,000/year, Silver €10,000/year, Bronze €5,000/year). Donations of €40 or more are tax-deductible in Belgium.

isala.be
Marketing channels6 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels2 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Personnel, Technology or R&D, Operations, Infrastructure, Marketing or Sales
Pricing details4 tiers
1Free participation with optional €10 donation for shipping
ModelFreemiumBilling cadenceOne time/ perpetual license
Notes

Participation in citizen-science studies is free. An optional €10 donation helps cover kit shipping costs. The kit itself, scientific analysis of swabs, and personal microbiome report remain free.

isala.be
2Gold Sponsorship: €20,000 per year
ModelSubscriptionBilling cadenceAnnual
Notes

Includes logo on website (1st position), four tickets to yearly Isala symposium, exclusive involvement as member of steering committee, invitations to interim events.

isala.be
3Silver Sponsorship: €10,000 per year
ModelSubscriptionBilling cadenceAnnual
Notes

Includes logo on website (2nd position) and two tickets to yearly Isala symposium.

isala.be
4Bronze Sponsorship: €5,000 per year
ModelSubscriptionBilling cadenceAnnual
Notes

Includes logo on website (3rd position) and one ticket to yearly Isala symposium.

isala.be
GTM typeB2C
B2C
Offering typeServices
Services
Brand1 of 13 records shown
1VIAB2L
Description

Study investigating the effect of vitamin B2 on women's health

isala.be
+12 more records
Core offering1 text field

Isala is a citizen-science research project at the University of Antwerp that uses DNA sequencing and bioinformatics to map and analyze the female vaginal microbiome. The project recruits adult women participants who self-collect vaginal, stool, skin, and saliva samples at home, which are analyzed in the lab using DNA barcoding, genome sequencing, and metabolomics. Participants receive personal microbiome reports and contribute to advancing women's health research across multiple daughter studies covering vitamins, menstrual products, menstrual cycle, family heritability, Ramadan fasting, yeast infections, and forensic applications.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 4 values shown
  • Nearly 6,000 registrations received within days of launching in 2020, making Isala the largest vaginal microbiome study in the world
+3 more records
Product overview1 text field

Isala is a citizen-science research initiative at the University of Antwerp studying the female microbiome through DNA technology. The core platform coordinates large-scale vaginal microbiome research with over 5,500 women participants. The project operates multiple daughter studies examining different aspects of vaginal health: Sisterhood (international expansion), Rufaida (Ramadan fasting effects), VIAB2L (vitamin B2 supplementation), Luna (menstrual products), EMIRA (menstrual cycle), Maggie (mother-daughter heritability), and DeVEnIR (yeast infections). Additionally, GeneDoe applies microbiome research to forensic science for sexual assault cases.

Product and service9 records
1Isala Core Research Platform
CategoryCore Research Platform
Description

A citizen-science research initiative at the University of Antwerp using advanced DNA sequencing technology to map and understand the female vaginal microbiome. Adult women participants self-collect vaginal, stool, skin, and saliva samples at home and receive personal microbiome reports in return.

2Isala Sisterhood
CategoryInternational Research Program
Description

International expansion program with sister projects in Peru (Laura), Switzerland (Marie), Cameroon (Leke), Nigeria (Dora), Morocco (Fatima), and Italy (Clelia) adapting Isala's citizen-science methodology to local contexts to study vaginal health across diverse populations.

3Rufaida (Ramadan) Study
CategoryDaughter Study
Description

Daughter study investigating the effects of Ramadan fasting on the vaginal microbiome and gut bacteria in Muslim women aged 18+. Participants provide samples before, during, and after Ramadan to understand how intermittent fasting affects the vaginal and gut microbiome.

4VIAB2L (Vitamins) Study
CategoryDaughter Study
Description

Intervention study examining the effect of vitamin B2 (riboflavine) and vitamin-producing lactobacilli on women's health, featuring the Limosilactobacillus reuteri AMBV339 bacterium identified through Isala research as a potential probiotic for women's health.

5Luna (Menstrual Products) Study
CategoryDaughter Study
Description

Daughter study examining how different menstrual hygiene products (pads, tampons, menstrual cups, underwear) affect the vaginal and vulvar microbiome. Adult Dutch-speaking women aged 18+ test five different menstrual products across five consecutive cycles.

6EMIRA (Menstrual Cycle) Study
CategoryDaughter Study
Description

Daughter study exploring changes in cervical mucus throughout the menstrual cycle and identifying which proteins are responsible for these changes, providing a new compass for understanding the menstrual cycle.

7Maggie (Family) Study
CategoryDaughter Study
Description

Daughter study investigating the heritability of vaginal bacteria between mothers and daughters, aiming to develop strategies for transferring beneficial vaginal bacteria to future generations to support women's health.

8DeVEnIR (Fungal Infections) Study
CategoryDaughter Study
Description

Daughter study investigating the role of the vaginal microbiome in recurrent vaginal yeast infections caused by Candida albicans, aiming for improved diagnostics and therapies, including development of vaginal vaccines against Candida.

9GeneDoe (Forensic) Project
CategoryDaughter Project
Description

Daughter project applying microbial fingerprinting as biological trace evidence in sexual assault cases, studying bacteria on underwear (and other garments) as forensic evidence. Microbial DNA is stable for up to 8 months and is more resistant to time and temperature than human DNA.

Scale indicator7 records

Each record includes

Type, Value, Description, Source

Partnership15 partners
Strategic tierCoreTypeStrategic or Co-development Partner
Description

Isala is a citizen-science project hosted within the Laboratory for Applied Microbiology and Biotechnology (LAMB) at the Faculty of Science of the University of Antwerp. The university provides the research infrastructure, lab facilities, staff, and institutional backing. Led by Prof. Sarah Lebeer since 2012.

2Biobank Antwerpen / Universitair Ziekenhuis Antwerpen
Strategic tierCoreTypeStrategic or Co-development Partner
Description

Samples are stored in the Biobank Antwerpen and Universitair Ziekenhuis Antwerpen for potential future scientific follow-up research, under strict ethical and privacy protocols.

isala.be
3Studentenvereniging Niyyah
Strategic tierMinorTypeStrategic or Co-development Partner
Description

Islamic student organization at the University of Antwerp that co-organized an iftar event and mini-symposium with Isala for about 50 women during Ramadan 2025, focusing on the Rufaida project.

isala.be
4Prof. Charlotte De Backer / MIOS UAntwerpen Research Group
Strategic tierCoreTypeStrategic or Co-development Partner
Description

Collaborates on questionnaire design, participant motivation, and science communication for Isala studies, particularly the Rufaida Ramadan study and VIAB2L vitamin study.

isala.be
Strategic tierMinorTypeStrategic or Co-development Partner
Description

Design partner that designed the Isala website and branding materials, including the visual identity and graphic design.

6Provincial Institute for Hygiene (PIH)
Strategic tierMinorTypeStrategic or Co-development Partner
Description

Collaborates with Isala to motivate participants and communicate about the importance of vaginal health, particularly within the Antwerp province.

isala.be
7Sensoa vzw
Strategic tierMinorTypeStrategic or Co-development Partner
Description

Flemish expertise center for sexual health that collaborates with Isala on science communication and participant engagement around women's health topics.

isala.be
8Laura Project (Peru)
Strategic tierCoreTypeStrategic or Co-development Partner
Description

Sister project in Peru led by Dra. Sandra Condori and Dra. Viviana Pinedo y Dra. Graciela Meza (Universidad de la Amazonía Peruana) and Dra. Theresa Ochoa (Universidad Peruana Cayetano Heredia). Studies vaginal microbiome in women from Lima and Iquitos. Coordinated by Sandra Condori from the Isala team.

isala.be
9Marie Project (Switzerland)
Strategic tierCoreTypeStrategic or Co-development Partner
Description

Sister project in Switzerland, coordinated by Sandra Condori from the Isala team, adapting the Isala citizen-science methodology for Swiss participants.

isala.be
10Leke Project (Cameroon)
Strategic tierCoreTypeStrategic or Co-development Partner
Description

Sister project in Cameroon led by Kenfack Josiane, investigating vaginal microbiome composition and exploring lactobacilli as probiotics in four groups: rural/urban women, HIV-positive and HIV-negative pregnant women. Named after Prof. Rose Leke.

isala.be
Strategic tierCoreTypeStrategic or Co-development Partner
Description

Sister project in Nigeria launched in 2024 with a symposium at Nnamdi Azikiwe University and an interactive radio show. Led by local researchers.

Strategic tierCoreTypeStrategic or Co-development Partner
Description

Sister project in Morocco focused on vaginal health and HPV research, part of the broader Isala sisterhood network.

Strategic tierCoreTypeStrategic or Co-development Partner
Description

Italian sister project coordinated by Vanessa Croatti, studying substances produced by beneficial vaginal bacteria and collaborating on the DeVEnIR daughter study.

Strategic tierCoreTypeStrategic or Co-development Partner
Description

International scientific association for probiotics and prebiotics. Several Isala team members are active in ISAPP: Sarah Lebeer is a board member, Sarah Ahannach is on the ISAPP-SFA organizing committee. The association provides conference platforms and awards for Isala researchers.

Strategic tierMinorTypeOthers
Description

Advisory board comprising UZA (University Hospital Antwerp), RZ Tienen, Femicare, Provincie Antwerpen, Endemic UA, and Eliza, providing medical, institutional, and strategic guidance to the Isala project.

Recent move6 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight3 records

Each record includes

Type, Description

Peers10 records
TypeEmerging player
Description

Biotechnology company using high-throughput microbial interaction screening to design microbial therapeutics, including in the women's health space. Comparable in applying advanced microbiome science to develop novel therapeutics, though focused on microbial combinations.

TypeEmerging player
Description

Clinical-stage microbiome therapeutics company developing Live Biotherapeutic Products for inflammatory diseases. Comparable as a microbiome-based therapeutic developer working with consortia of commensal bacteria.

TypeBroad incumbent
Description

Pioneer in microbiome-based therapeutics, now part of Ferring Pharmaceuticals, with expertise in Live Biotherapeutic Products. Comparable in microbiome therapeutic development capability within the women's health ecosystem.

TypeEmerging player
Description

Biotechnology company developing precision microbiome medicines using engineered phage and bacteriocins. Comparable in applying cutting-edge microbiome science for therapeutic applications, though focused on engineered approaches rather than natural isolates.

5Second Genome
TypeBroad incumbent
Description

Clinical-stage biopharmaceutical company identifying and validating novel therapeutic targets from the microbiome. Comparable in applying microbiome science to drug discovery, though focused on small molecule therapeutics rather than live biotherapeutics.

6Yaso Therapeutics
TypeEmerging player
Description

Women's health-focused biotechnology company developing microbiome-based therapeutics for gynecological conditions. Comparable in targeting vaginal microbiome to address unmet women's health needs, though at a more commercial development stage.

TypeBroad incumbent
Description

Clinical-stage biotechnology company developing oral microbiome-based medicines for inflammatory diseases. Comparable in developing microbiome-based therapeutics using commensal bacteria, though focused on systemic indications.

TypeDirect peer
Description

Clinical-stage biopharmaceutical company developing microbiome-based therapeutics for women's health, including Lactin-V (Lactobacillus crispatus CTV-05) for bacterial vaginosis. Directly comparable as a vaginal microbiome therapeutic developer, though operating as a commercial entity rather than academic research project.

TypeBroad incumbent
Description

Global pharmaceutical company with significant women's health and reproductive medicine portfolio, including microbiome-focused investments. Comparable as a large player in women's health therapeutics, though operating across multiple therapeutic areas.

TypeEmerging player
Description

Citizen-science project at UC San Diego focused on characterizing the human gut microbiome through large-scale public participation. Comparable as a large-scale microbiome citizen-science research initiative using crowdsourced sampling and DNA sequencing, though focused on gut rather than vaginal microbiome.

Market position
Strengths4 records

Each record includes

Headline, Details, Source

Weaknesses4 records

Each record includes

Headline, Details, Source

Competitive moat5 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers2 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment4 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile3 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
No
API detail
Has APIbool
No

Docs URL, Description

Integration2 records

Each record includes

Title, Type, Description, Source

AI maturity
App detail

Has app

Feature5 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles19 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

Subsidiaries6 records

Each record includes

Name, Acquired on, Relationship type, Type, Business focus

Compliance1 record

Each record includes

Name, Class, Description

Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Isala

Microbiome Researchisala.be

Isala firmographics

Firmographics
Name
Isala
Legal name
Isala
Website
https://isala.be
Company type
Private
Founded year
2020
Operating status
Operating
Headcount range
11–50 employees
Ownership category
akta.pro rank

Isala industry classification

Industry
Product category
Microbiome Research
NAICS
Medical Laboratories (621511)
SIC
In Vitro & In Vivo Diagnostic Substances (2835)
akta.pro industry
PRIMARYHLAAAFAH
Microbiome Diagnostics & Biomarker Platforms (gut/skin/oral/vaginal)
SECONDARYHLAAAFAI
Microbiome Analytics, Sequencing & Bioinformatics Platforms
SECONDARYHLAGANAH
Microbiome & Metagenomics Services
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Specialty Lab Services (Genomics/Proteomics/Cellomics)
SECONDARYHLAAAFAK
Microbiome Clinical Development & Translational Services (trial design, endpoints, sampling)
SECONDARYHLAGANAA
Genomics & Next-Generation Sequencing (NGS) Services
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Specialty Lab Services (Genomics/Proteomics/Cellomics)

Keywords

  • Vaginal microbiome research
  • Citizen science platform
  • Women's health research
  • DNA sequencing analysis
  • Microbiome mapping

Where Isala is headquartered

Location

Headquarters

HQ city
Antwerp
HQ country
Belgium
HQ region
Europe

Offices1 record

Markets served

Isala business model

Business model
GTM type
B2C
Offering type
Services
Cost components
Personnel, Technology or R&D, Operations, Infrastructure, Marketing or Sales

Revenue model

  1. Research Grants and Institutional Funding: Isala is primarily funded through research grants from institutional sources. Primary funding comes from the European Research Council (ERC) under Horizon 2020 (Grant agreement 852600 Lacto-Be). Additional funding from the University of Antwerp, and project-specific grants such as the Biocodex Microbiota Foundation Belux Grant 2024. The project also receives support through donations and sponsorship packages (Gold €20,000/year, Silver €10,000/year, Bronze €5,000/year). Donations of €40 or more are tax-deductible in Belgium.

Pricing tiers

ModelBillingPrice
FreemiumOne time/ perpetual licenseFree participation with optional €10 donation for shipping
SubscriptionAnnualGold Sponsorship: €20,000 per year
SubscriptionAnnualSilver Sponsorship: €10,000 per year
SubscriptionAnnualBronze Sponsorship: €5,000 per year

Go-to-market motion1 record

Distribution channels2 records

Marketing channels6 records

Isala product offering

Product offering

Core offering

Isala is a citizen-science research project at the University of Antwerp that uses DNA sequencing and bioinformatics to map and analyze the female vaginal microbiome. The project recruits adult women participants who self-collect vaginal, stool, skin, and saliva samples at home, which are analyzed in the lab using DNA barcoding, genome sequencing, and metabolomics. Participants receive personal microbiome reports and contribute to advancing women's health research across multiple daughter studies covering vitamins, menstrual products, menstrual cycle, family heritability, Ramadan fasting, yeast infections, and forensic applications.

Product overview

Isala is a citizen-science research initiative at the University of Antwerp studying the female microbiome through DNA technology. The core platform coordinates large-scale vaginal microbiome research with over 5,500 women participants. The project operates multiple daughter studies examining different aspects of vaginal health: Sisterhood (international expansion), Rufaida (Ramadan fasting effects), VIAB2L (vitamin B2 supplementation), Luna (menstrual products), EMIRA (menstrual cycle), Maggie (mother-daughter heritability), and DeVEnIR (yeast infections). Additionally, GeneDoe applies microbiome research to forensic science for sexual assault cases.

Differentiator

Problem solved

Functional benefit

Brands

  • VIAB2L: Study investigating the effect of vitamin B2 on women's health
  • Luna
  • EMIRA
  • Rufaida
  • DeVEnIR
  • Maggie
  • GeneDoe
  • Leke
  • Laura
  • Marie
  • Dora
  • Fatima
  • Clelia

Products and services

  • Isala Core Research Platform A citizen-science research initiative at the University of Antwerp using advanced DNA sequencing technology to map and understand the female vaginal microbiome. Adult women participants self-collect vaginal, stool, skin, and saliva samples at home and receive personal microbiome reports in return.
  • Isala Sisterhood International expansion program with sister projects in Peru (Laura), Switzerland (Marie), Cameroon (Leke), Nigeria (Dora), Morocco (Fatima), and Italy (Clelia) adapting Isala's citizen-science methodology to local contexts to study vaginal health across diverse populations.
  • Rufaida (Ramadan) Study Daughter study investigating the effects of Ramadan fasting on the vaginal microbiome and gut bacteria in Muslim women aged 18+. Participants provide samples before, during, and after Ramadan to understand how intermittent fasting affects the vaginal and gut microbiome.
  • VIAB2L (Vitamins) Study Intervention study examining the effect of vitamin B2 (riboflavine) and vitamin-producing lactobacilli on women's health, featuring the Limosilactobacillus reuteri AMBV339 bacterium identified through Isala research as a potential probiotic for women's health.
  • Luna (Menstrual Products) Study Daughter study examining how different menstrual hygiene products (pads, tampons, menstrual cups, underwear) affect the vaginal and vulvar microbiome. Adult Dutch-speaking women aged 18+ test five different menstrual products across five consecutive cycles.
  • EMIRA (Menstrual Cycle) Study Daughter study exploring changes in cervical mucus throughout the menstrual cycle and identifying which proteins are responsible for these changes, providing a new compass for understanding the menstrual cycle.
  • Maggie (Family) Study Daughter study investigating the heritability of vaginal bacteria between mothers and daughters, aiming to develop strategies for transferring beneficial vaginal bacteria to future generations to support women's health.
  • DeVEnIR (Fungal Infections) Study Daughter study investigating the role of the vaginal microbiome in recurrent vaginal yeast infections caused by Candida albicans, aiming for improved diagnostics and therapies, including development of vaginal vaccines against Candida.
  • GeneDoe (Forensic) Project Daughter project applying microbial fingerprinting as biological trace evidence in sexual assault cases, studying bacteria on underwear (and other garments) as forensic evidence. Microbial DNA is stable for up to 8 months and is more resistant to time and temperature than human DNA.

Quantifiable outcome

  • Nearly 6,000 registrations received within days of launching in 2020, making Isala the largest vaginal microbiome study in the world
  • +3 more outcomes

Companies that use Isala

Customer profile

Named customers2 records

Segments4 records

Ideal customer profiles3 records

Isala technology and API

Technology

Technology focussed No

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Integration2 records

Feature5 records

Isala partnerships and signals

Strategic signal

Partnerships

15 partnerships are on record, tiered core and minor.

  • University of AntwerpcoreStrategic or Co-development PartnerIsala is a citizen-science project hosted within the Laboratory for Applied Microbiology and Biotechnology (LAMB) at the Faculty of Science of the University of Antwerp. The university provides the research infrastructure, lab facilities, staff, and institutional backing. Led by Prof. Sarah Lebeer since 2012.
  • Biobank Antwerpen / Universitair Ziekenhuis AntwerpencoreStrategic or Co-development PartnerSamples are stored in the Biobank Antwerpen and Universitair Ziekenhuis Antwerpen for potential future scientific follow-up research, under strict ethical and privacy protocols.
  • Studentenvereniging NiyyahminorStrategic or Co-development PartnerIslamic student organization at the University of Antwerp that co-organized an iftar event and mini-symposium with Isala for about 50 women during Ramadan 2025, focusing on the Rufaida project.
  • Prof. Charlotte De Backer / MIOS UAntwerpen Research GroupcoreStrategic or Co-development PartnerCollaborates on questionnaire design, participant motivation, and science communication for Isala studies, particularly the Rufaida Ramadan study and VIAB2L vitamin study.
  • Studio MariaminorStrategic or Co-development PartnerDesign partner that designed the Isala website and branding materials, including the visual identity and graphic design.
  • Provincial Institute for Hygiene (PIH)minorStrategic or Co-development PartnerCollaborates with Isala to motivate participants and communicate about the importance of vaginal health, particularly within the Antwerp province.
  • Sensoa vzwminorStrategic or Co-development PartnerFlemish expertise center for sexual health that collaborates with Isala on science communication and participant engagement around women's health topics.
  • Laura Project (Peru)coreStrategic or Co-development PartnerSister project in Peru led by Dra. Sandra Condori and Dra. Viviana Pinedo y Dra. Graciela Meza (Universidad de la Amazonía Peruana) and Dra. Theresa Ochoa (Universidad Peruana Cayetano Heredia). Studies vaginal microbiome in women from Lima and Iquitos. Coordinated by Sandra Condori from the Isala team.
  • Marie Project (Switzerland)coreStrategic or Co-development PartnerSister project in Switzerland, coordinated by Sandra Condori from the Isala team, adapting the Isala citizen-science methodology for Swiss participants.
  • Leke Project (Cameroon)coreStrategic or Co-development PartnerSister project in Cameroon led by Kenfack Josiane, investigating vaginal microbiome composition and exploring lactobacilli as probiotics in four groups: rural/urban women, HIV-positive and HIV-negative pregnant women. Named after Prof. Rose Leke.
  • Dora Project (Nigeria)coreStrategic or Co-development PartnerSister project in Nigeria launched in 2024 with a symposium at Nnamdi Azikiwe University and an interactive radio show. Led by local researchers.
  • Fatima Project (Morocco)coreStrategic or Co-development PartnerSister project in Morocco focused on vaginal health and HPV research, part of the broader Isala sisterhood network.
  • Clelia Project (Italy)coreStrategic or Co-development PartnerItalian sister project coordinated by Vanessa Croatti, studying substances produced by beneficial vaginal bacteria and collaborating on the DeVEnIR daughter study.
  • ISAPP (International Scientific Association for Probiotics and Prebiotics)coreStrategic or Co-development PartnerInternational scientific association for probiotics and prebiotics. Several Isala team members are active in ISAPP: Sarah Lebeer is a board member, Sarah Ahannach is on the ISAPP-SFA organizing committee. The association provides conference platforms and awards for Isala researchers.
  • Advisory Board Partners (UZA, RZ Tienen, Femicare, Provincie Antwerpen, Endemic UA, Eliza)minorOthersAdvisory board comprising UZA (University Hospital Antwerp), RZ Tienen, Femicare, Provincie Antwerpen, Endemic UA, and Eliza, providing medical, institutional, and strategic guidance to the Isala project.

Scale indicators7 records

Recent moves6 records

Expansion highlights3 records

Isala competitors and assessment

Company assessment

Emerging players

  • Concerto Biosciences: Biotechnology company using high-throughput microbial interaction screening to design microbial therapeutics, including in the women's health space. Comparable in applying advanced microbiome science to develop novel therapeutics, though focused on microbial combinations.
  • Siolta Therapeutics: Clinical-stage microbiome therapeutics company developing Live Biotherapeutic Products for inflammatory diseases. Comparable as a microbiome-based therapeutic developer working with consortia of commensal bacteria.
  • Eligo Bioscience: Biotechnology company developing precision microbiome medicines using engineered phage and bacteriocins. Comparable in applying cutting-edge microbiome science for therapeutic applications, though focused on engineered approaches rather than natural isolates.
  • Yaso Therapeutics: Women's health-focused biotechnology company developing microbiome-based therapeutics for gynecological conditions. Comparable in targeting vaginal microbiome to address unmet women's health needs, though at a more commercial development stage.
  • American Gut Project: Citizen-science project at UC San Diego focused on characterizing the human gut microbiome through large-scale public participation. Comparable as a large-scale microbiome citizen-science research initiative using crowdsourced sampling and DNA sequencing, though focused on gut rather than vaginal microbiome.

Broad incumbents

  • Rebiotix (Ferring): Pioneer in microbiome-based therapeutics, now part of Ferring Pharmaceuticals, with expertise in Live Biotherapeutic Products. Comparable in microbiome therapeutic development capability within the women's health ecosystem.
  • Second Genome: Clinical-stage biopharmaceutical company identifying and validating novel therapeutic targets from the microbiome. Comparable in applying microbiome science to drug discovery, though focused on small molecule therapeutics rather than live biotherapeutics.
  • Evelo Biosciences: Clinical-stage biotechnology company developing oral microbiome-based medicines for inflammatory diseases. Comparable in developing microbiome-based therapeutics using commensal bacteria, though focused on systemic indications.
  • Ferring Pharmaceuticals: Global pharmaceutical company with significant women's health and reproductive medicine portfolio, including microbiome-focused investments. Comparable as a large player in women's health therapeutics, though operating across multiple therapeutic areas.

Direct peers

  • Osel Inc. Clinical-stage biopharmaceutical company developing microbiome-based therapeutics for women's health, including Lactin-V (Lactobacillus crispatus CTV-05) for bacterial vaginosis. Directly comparable as a vaginal microbiome therapeutic developer, though operating as a commercial entity rather than academic research project.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat5 records

Key risks6 records

Key highlights7 records

Customer concentration

Isala social profiles

Digital presence

Isala compliance and trust

Trust signal

Compliance1 record

Isala financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Isala leadership team

Management profile

Number of profiles

Profiles19 records

Isala subsidiaries and ownership

Company hierarchy

Subsidiaries6 records

Isala funding detail

Funding detail

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Isala M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Isala

What does Isala do?

Isala is a citizen-science research project at the University of Antwerp that uses DNA sequencing and bioinformatics to map and analyze the female vaginal microbiome. The project recruits adult women participants who self-collect vaginal, stool, skin, and saliva samples at home, which are analyzed in the lab using DNA barcoding, genome sequencing, and metabolomics. Participants receive personal microbiome reports and contribute to advancing women's health research across multiple daughter studies covering vitamins, menstrual products, menstrual cycle, family heritability, Ramadan fasting, yeast infections, and forensic applications.

Is Isala a public or private company?

Isala is a private company. It is classified as corporate owned and is currently operating.

When was Isala founded?

Isala was founded in 2020. It employs 11 to 50 people.

Where is Isala based?

Isala is headquartered in Antwerp, Belgium, in the Europe region.

How does Isala make money?

One revenue line is on record: research Grants and Institutional Funding.

Who are Isala's main competitors?

Emerging players on record are Concerto Biosciences, Siolta Therapeutics, Eligo Bioscience, Yaso Therapeutics and American Gut Project. Broad incumbents are Rebiotix (Ferring), Second Genome, Evelo Biosciences and Ferring Pharmaceuticals. Osel Inc. is listed as a direct peer.

Does Isala have an API?

No public API is recorded for Isala.

What industry is Isala in?

Isala's product category is Microbiome Research. Its primary akta.pro industry code is HLAAAFAH, Microbiome Diagnostics & Biomarker Platforms (gut/skin/oral/vaginal), with a secondary code of HLAAAFAI, Microbiome Analytics, Sequencing & Bioinformatics Platforms. Its NAICS code is 621511 and its SIC code is 2835.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales